European equity markets opened lower on Tuesday, reflecting heightened inflation worries sparked by a jump in oil prices and fresh uncertainty surrounding a prolonged Middle East conflict. The pan‑European STOXX 600 slipped 0.2% to 648.41 points by 0705 GMT, while Germany’s DAX fell 0.3%, France’s CAC 40 dropped 0.4%, and London’s FTSE remained flat after a subdued session on Monday caused by a U.S. public holiday.
Oil price surge fuels inflation fears
Brent crude futures rose to $98.5 per barrel after Iran warned it would retaliate against any further attacks by targeting energy infrastructure across the Gulf, including U.S. oil and gas assets. Higher energy costs are feeding concerns that inflation could remain stubbornly high, a scenario that traditionally pressures central banks and dampens investor sentiment.
Novartis hit by double drug‑development disappointment
Swiss pharmaceutical giant Novartis saw its shares tumble 8.8% after announcing that late‑stage testing of its experimental therapy del‑desiran for myotonic dystrophy failed to meet the primary endpoint. This setback follows a previous disappointment announced on Monday, when the company’s cholesterol‑lowering candidate pelacarsen also missed its primary goals in a late‑stage trial. The twin failures underscore the inherent risk in biotech research and have weighed heavily on the market’s health‑care segment.
Other movers in the market
Among individual stocks, Sandoz, another Swiss pharma firm, added 2.9% after it outlined a plan to more than double net sales between 2025 and 2035, signaling confidence in its growth strategy despite sector headwinds. In Italy, state‑owned postal operator Poste Italiane sweetened its takeover offer for Telecom Italia as it seeks to secure control of the former phone monopoly, though its own shares slipped 0.2%.
Broader market context
The modest decline in European equities comes amid a broader backdrop of mixed economic data and geopolitical tension. While oil price spikes typically boost energy‑sector earnings, they also raise input costs for manufacturers and consumers, feeding into inflation narratives that can prompt tighter monetary policy. Investors are therefore balancing the upside for energy stocks against the downside risk to broader consumer‑price sensitive sectors.
Outlook
Analysts note that if oil prices remain elevated, inflation expectations could stay high, potentially influencing European central banks to adopt a more hawkish stance. Meanwhile, the pharmaceutical sector will be watching Novartis closely to see how the company reallocates resources after the twin trial failures. Market participants will also monitor the evolving situation in the Middle East, as any escalation could further impact oil markets and, by extension, global inflation dynamics.
Overall, the European market’s modest dip reflects a cautious investor mood, with higher energy costs and drug‑development setbacks serving as the primary drag on performance.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
